列联管理对接受阿片类药物治疗患者的疗效:系统综述与荟萃分析
该系统综述与荟萃分析纳入74项报告(10 444名成人)显示,列联管理(基于客观验证行为改变给予物质激励)与接受阿片类药物治疗(MOUD)患者治疗结束时6类临床问题均相关,其中4类效应量为中到大,2类为小到中;合并分析显示对戒断和治疗依从性均为中等效应。结论支持在MOUD患者中使用列联管理,并呼吁政策促进其融入社区服务。
要点
- 列联管理对MOUD患者治疗结束时的6类临床问题均显示关联效应。
- 兴奋剂使用、吸烟、非法阿片使用和用药依从性效应量为中到大。
- 多物质使用和治疗出席效应量为小到中,合并戒断与依从性均为中等效应。
核心结论
- 列联管理与接受MOUD患者治疗结束时6类临床问题均相关,支持其用于应对包括兴奋剂误用在内的关键临床问题。
研究设计与样本
- 系统检索PubMed、Cochrane CENTRAL、Web of Science及参考文献至2020年5月5日,纳入接受MOUD患者中基于金钱的列联管理前瞻性实验研究。
- 共识别1443篇报告,74篇(10 444名独特成人参与者)纳入叙述性综述,60篇纳入荟萃分析,采用随机效应模型。
主要发现
- 列联管理与6类问题分别均相关:兴奋剂使用Cohen d=0.70(95%CI 0.49-0.92),吸烟d=0.78(95%CI 0.43-1.14),非法阿片使用d=0.58(95%CI 0.30-0.86),用药依从性d=0.75(95%CI 0.30-1.21)。
- 多物质使用d=0.46(95%CI 0.30-0.62),治疗出席d=0.43(95%CI 0.22-0.65)。
- 合并戒断类别Cohen d=0.58(95%CI 0.47-0.69),合并治疗依从性类别d=0.62(95%CI 0.40-0.84)。
临床怎么用
- 对于接受MOUD的患者,可考虑使用列联管理以改善兴奋剂使用、吸烟、非法阿片使用、用药依从性、多物质使用和治疗出席。
- 政策层面需促进列联管理融入社区MOUD服务。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Medication treatment for opioid use disorder (MOUD) is efficacious, but comorbid stimulant use and other behavioral health problems often undermine efficacy. OBJECTIVE: To examine the association of contingency management, a behavioral intervention wherein patients receive material incentives contingent on objectively verified behavior change, with end-of-treatment outcomes for these comorbid behavioral problems. DATA SOURCES: A systematic search of PubMed, Cochrane CENTRAL, Web of Science, and reference sections of articles from inception through May 5, 2020. The following search terms were used: vouchers OR contingency management OR financial incentives. STUDY SELECTION: Prospective experimental studies of monetary-based contingency management among participants receiving MOUD. DATA EXTRACTION AND SYNTHESIS: Following Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline, 3 independent investigators extracted data from included studies for a random-effects meta-analysis. MAIN OUTCOMES AND MEASURES: Primary outcome was the association of contingency management at end-of-treatment assessments with 6 clinical problems: stimulant use, polysubstance use, illicit opioid use, cigarette smoking, therapy attendance, and medication adherence. Random-effects meta-analysis models were used to compute weighted mean effect size estimates (Cohen d) and corresponding 95% CIs separately for each clinical problem and collapsing across the 3 categories assessing abstinence and the 2 assessing treatment adherence outcomes. RESULTS: The search identified 1443 reports of which 74 reports involving 10 444 unique adult participants met inclusion criteria for narrative review and 60 for inclusion in meta-analyses. Contingency management was associated with end-of-treatment outcomes for all 6 problems examined separately, with mean effect sizes for 4 of 6 in the medium-large range (stimulants, Cohen d = 0.70 [95% CI, 0.49-0.92]; cigarette use, Cohen d = 0.78 [95% CI, 0.43-1.14]; illicit opioid use, Cohen d = 0.58 [95% CI, 0.30-0.86]; medication adherence, Cohen d = 0.75 [95% CI, 0.30-1.21]), and 2 in the small-medium range (polysubstance use, Cohen d = 0.46 [95% CI, 0.30-0.62]; therapy attendance, d = 0.43 [95% CI, 0.22-0.65]). Collapsing across abstinence and adherence categories, contingency management was associated with medium effect sizes for abstinence (Cohen d = 0.58; 95% CI, 0.47-0.69) and treatment adherence (Cohen d = 0.62; 95% CI, 0.40-0.84) compared with controls. CONCLUSIONS AND RELEVANCE: These results provide evidence supporting the use of contingency management in addressing key clinical problems among patients receiving MOUD, including the ongoing epidemic of comorbid psychomotor stimulant misuse. Policies facilitating integration of contingency management into community MOUD services are sorely needed.
引用
- Bolívar HA, Klemperer EM, Coleman SRM, et al. Contingency Management for Patients Receiving Medication for Opioid Use Disorder: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2021. PMID: 34347030. doi:10.1001/jamapsychiatry.2021.1969
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。